NRIX Stock Forecast & Price Target

Nurix Therapeutics is attractive because its lead asset bexobrutideg has shown encouraging clinical efficacy in CLL, while multiple core programs remain on track, including studies in CLL, NHL, WM, MS and CSU, supporting a de-risked and increasingly diversified pipeline. Strong strategic validation from Roche, Sanofi, Gilead and Pfizer produced $673.1M in collaboration and license revenue in F3Q26, and the company ended the quarter with approximately $1.1B in cash, which should support development and extend runway into 2H29. The combination of targeted protein degradation expertise, an AI-enabled discovery platform, and incremental progress from NX-1607 and STAT6/IRAK4 programs creates meaningful long-term optionality in oncology and inflammatory diseases.

Nurix Therapeutics is a clinical-stage biotech with no revenues, so its value depends heavily on unproven pipeline assets rather than current operating cash flow. The outlook is negative because the model assigns only a 75% probability of approval for bexobrutideg and a 5% probability for NX-1607, while key risks include negative clinical data, safety concerns, delayed approval, weak market uptake, partnership risk, and long-term dilution. The company’s spending also appears pressured by one-time Roche-related consulting and business development expenses, and the downside case implies bexobrutideg could fail to show competitive durability or safety, leaving the stock closer to net cash with minimal pipeline value.